KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.

Christina L Runge, Jessica A Lyness, Maura L Gillison, David J Adelstein, Paul M Harari, Jolie Ringash, Jessica L Geiger, Greg A Krempl, Dukagjin M Blakaj, James Edward Bates, Thomas J Galloway, Christopher U Jones, Michael F Gensheimer, Neal E Dunlap, Jack Phan, Jimmy J Caudell, J Daniel Pennington, Pedro A Torres-Saavedra, Sue S Yom, Quynh-Thu Le, Benjamin Movsas

Int J Radiat Oncol Biol Phys 124(1) 61-69

PMID40829719
PMCIDPMC12637033
DOI10.1016/j.ijrobp.2025.08.021
发表日期2025-08-19
入排依据:The report is from a Phase III randomized oncology trial with drug intervention, but the reported results are for a patient-reported secondary endpoint (hearing handicap), not a time-to-event efficacy endpoint. The deterministic review correctly identified no time-to-event signal.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2.:非 KM 图。
摘要

摘要

PURPOSE: RTOG 1016 was a noninferiority phase III trial comparing the efficacy of radiation with either cisplatin (RT + Cis) or cetuximab (RT + Cetux) for patients with Humman Papillomavirus (HPV)+ oropharyngeal cancer (OPC). Perceived hearing handicap was included as a patient-reported outcome (PRO) secondary endpoint. The primary hypothesis was that perceived hearing handicap would be greater for patients receiving RT + Cis compared with RT + Cetux. METHODS AND MATERIALS: Perceived hearing handicap was measured at baseline, end of treatment, and 3, 6, and 12 months posttreatment using the Hearing Handicap Inventory for Adults Screening Version (HHIA-S), a 10-item self-assessment questionnaire designed to measure patients' reactions to their hearing loss. Mixed ordinal logistic models were used to determine the treatment effect on HHIA-S scores and handicap categories (2-sided α = 0.05). RESULTS: The PRO substudy included 375 eligible patients. No significant differences in patient/tumor characteristics were found between patients who participated in the HHIA-S study versus those excluded. For total HHIA-S scores and social and emotional subscales, RT + Cetux had significantly lower (ie, better) scores from end of treatment. Change score from baseline to end of treatment for RT + Cis (4.32; 95% confidence interval [CI], 2.57-6.07]) was greater than RT + Cetux (0.08; 95% CI, -1.15 to 1.31). For hearing handicap category, RT + Cis had a significantly higher percentage of mild/moderate and severe cases at the end of treatment (32%) compared with RT + Cetux (20%) (P < .0001). Adjusted conditional odds of higher self-perceived hearing handicap category for RT + Cis compared with RT + Cetux was 3.73 (95% CI, 2.10-6.62). CONCLUSION: Patients have significantly worse self-perceived hearing handicap after receiving RT + Cis treatment than with RT + Cetux. This was consistent across time through 1 year posttreatment. These findings inform hearing-related outcomes for patients with HPV-associated OPC and indicate the need for ototoxicity monitoring with RT + Cis treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1(A) Mean and 95% confidence interval (CI) of total HHIA-S scores across time by treatment arm — the higher the score the more self-perceived hearing handicap. The number of subjects who completed the HHIA-S form is indicated at each time point. (B) Histogram of total HHIA-S scores across time by treatment arm. The number of subjects who completed the HHIA-S form is indicated at each time point. The dotted line on the histograms represents the mean total HHIA-S scores (SD=Standard Deviation) — the higher the score the more self-perceived hearing handicap.
非 KM Figure
Figure 2.Sankey plot of HHIA-S handicap categories across time by treatment arm in NRG/RTOG 1016. The arcs between bars represent the flow of patients between handicap categories over time.
非 KM Figure